Cytokine blocking agents in dermatology

Clinical and Experimental Dermatology

Volumn 27, Issue 7, 2002, Pages 585-590

  Williams, Jason D L ^a,b   Griffiths, C E M ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE BLOCKING AGENT; DERMATOLOGICAL AGENT; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BEHCET DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; GRAFT VERSUS HOST REACTION; MEDICAL PRACTICE; MUCOUS MEMBRANE PEMPHIGOID; PRIORITY JOURNAL; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; SAPHO SYNDROME; SCLERODERMA; SKIN DISEASE; SUBCORNEAL PUSTULAR DERMATOSIS; SUPPURATIVE HIDRADENITIS; TOXIC EPIDERMAL NECROLYSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CYTOKINES; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN DISEASES;

EID: 0036456513     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2002.01149.x     Document Type: Review

References (32)

1. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone, I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-57.
2. Vollmer S, Menssen A, Trommler P, Schendel D, Prinz JC. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 1994; 24: 2377-82.
3. Ohmen JD, Hanifin JM, Nickoloff BJ et al. Over expression of Il-10 in atopic dermatitis. J Immunol 1995; 154: 1956-63.
4. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-humoral chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-53.
5. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumour necrosis factor-α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000; 42: 829-30.
6. Kirby B, Marsland AM, Carmichael AJ, Griffiths CEM. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001; 26: 27-9.
7. Ogilvie ALJ, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001; 144: 587-9.
8. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet, 2001; 357: 1842-7.
9. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
10. Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis. Lancet 2002; 359: 1252.
11. Sayinalp N, Özcebe OI, Özdemir OP, Haznedaroglu IC, Dündar S. Kirazhi. Cytokines in Behçet's disease. J Rheumatol 1996; 23: 321-2.
12. Goossens PH, Verbug RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor α blocking therapy. Ann Rheum Dis 2001; 60: 637.
13. Rozenbaum M, Rosner I, Portnoy E. Remission of Behçet's Syndrome with TNF-α blocking treatment. Ann Rheum Dis 2002; 61: 283-4.
14. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's Syndrome with infliximab. Rheumatology 2001; 40: 473-4.
15. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti-tumor necrosis factor-α monoclonal antibody. Arch Dermatol 2001; 137: 930-3.
16. Kobbe G, Scheider P, Rohr U et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNF-α antibody. Bone Marrow Transplant 2001; 28: 47-9.
17. Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini F. Successful treatment of SAPHO syndrome with infliximab: Report of two cases. Ann Rheum Dis 2002; 61: 375-6.
18. Grob JJ, Mege JL, Capo C et al. Role of tumour necrosis factor-α in Sneddon-Wilkinson subcorneal pustular dermatosis. J Am Acad Dermatol 1991; 25: 944-7.
19. Voigtlander C, Luftl M, Schuler G, Hertl M. Infliximab, A novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson Disease). Arch Dermatol 2001; 137: 1571-4.
20. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-α antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002; 146: 707-8.
21. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: Response to treatment with infliximab. Inflamm Bowel Dis 2001; 7: 323-6.
22. Mohler LM, Torrence DS, Smith CA et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxaemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548-61.
23. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000; 356: 385-90.
24. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: Observations on combination therapy. Br J Dermatol 2002; 146: 118-21.
25. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-9.
26. Ellman MH, MacDonald PA, Hayes FA. Etanercept as treatment for diffuse scleroderma: A pilot study. Arthritis Rheum 2000; 43 (Suppl.): S392 (Abstract).
27. Sacher C, Rubbert A, Konig C, Scherffetter-Kochanek K, Krieg T, Hunzelmann N. Treatment of recalcitrant cicatricial pemphigoid with tumor necrosis factor α antagonist etanercept. J Am Acad Dermatol 2002; 46: 113-5.
28. Smith KJ, Skelton H. Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-α receptor fusion protein. Br J Dermatol 2001; 144: 597-600.
29. Aukrust P, Lien E, Kristofferson AK et al. Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency: Possible immunologic and clinical consequences. Blood 1996; 87: 674-81.
30. Lhoner ME, Krueger J. Gottlieb et al. Clinical trials of a fully human anti-IL-S antibody for the treatment of psoriasis. Br J Dermatol 1999; 141: 989 (Abstract).
31. Shah M, Foreman DM, Ferguson MW. Control of scarring in adult wounds by neutralising antibody to transforming growth factor-β. Lancet 1992; 339: 213-4.
32. Shah M, Foreman DM, Ferguson MW. Neutralising antibody to TGF-β 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 1994; 107: 1137-57.